Azra Raza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7053591/publications.pdf

Version: 2024-02-01

83 papers	9,505 citations	136950 32 h-index	91884 69 g-index
84 all docs	84 docs citations	84 times ranked	9120 citing authors

#	Article	IF	Citations
1	Subversion of Serotonin Receptor Signaling in Osteoblasts by Kynurenine Drives Acute Myeloid Leukemia. Cancer Discovery, 2022, 12, 1106-1127.	9.4	12
2	SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	26
3	Mutation in SF3B1 gene promotes formation of polyploid giant cells in Leukemia cells. Medical Oncology, 2022, 39, 65.	2.5	7
4	Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusionâ€“Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. Journal of Clinical Oncology, 2021, 39, 48-56.	1.6	80
5	On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs). Blood, 2021, 138, 2598-2598.	1.4	3
6	Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. Blood, 2020, 136, 17-17.	1.4	4
7	Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1. Molecular Cell, 2019, 76, 82-95.e7.	9.7	84
8	Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11978-11987.	7.1	90
9	Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. Blood, 2019, 134, 4248-4248.	1.4	2
10	Survey and evaluation of mutations in the human KLF1 transcription unit. Scientific Reports, 2018, 8, 6587.	3.3	5
11	Improving Treatment for Myelodysplastic Syndromes Patients. Current Treatment Options in Oncology, 2018, 19, 66.	3.0	12
12	Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes. Blood Advances, 2018, 2, 1393-1402.	5.2	20
13	Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 2735-2735.	1.4	5
14	Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive. Blood, 2018, 132, 463-463.	1.4	9
15	Pharmacological Targeting of Osteoblast-Induced MDS and AML. Blood, 2018, 132, 5235-5235.	1.4	1
16	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. Journal of Hematology and Oncology, 2017, 10, 55.	17.0	302
17	Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Leukemia Research, 2017, 52, 50-57.	0.8	25
18	U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3â€² End Formation. Molecular Cell, 2016, 62, 479-490.	9.7	111

#	Article	IF	Citations
19	Physiologic Expression of Sf3b1 K700E Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell, 2016, 30, 404-417.	16.8	318
20	Two different â€œtalesâ€•of ATG7: Clinical relevance to myelodysplastic syndromes. Molecular and Cellular Oncology, 2016, 3, e1212686.	0.7	3
21	Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica, 2016, 101, 781-788.	3.5	50
22	Activity of the oral mitogenâ€activated protein kinase kinase inhibitor trametinib in <scp>RAS</scp>â€mutant relapsed or refractory myeloid malignancies. Cancer, 2016, 122, 1871-1879.	4.1	113
23	Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood, 2016, 128, 2011-2011.	1.4	3
24	Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.. Journal of Clinical Oncology, 2016, 34, 7012-7012.	1.6	1
25	Prognostic significance of neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in myelodysplastic syndromes.. Journal of Clinical Oncology, 2016, 34, 7062-7062.	1.6	2
26	Comparison of International Prognostic Scoring System (IPSS) and Revised IPSS (IPSS-R) in myelodysplastic syndromes (MDS).. Journal of Clinical Oncology, 2016, 34, e18549-e18549.	1.6	0
27	Prognostic significance of bone marrow cellularity in myelodysplastic syndromes: a retrospective analysis.. Journal of Clinical Oncology, 2016, 34, e18550-e18550.	1.6	0
28	INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs)â€”Study design informed by subgroup analyses of ONTIME.. Journal of Clinical Oncology, 2016, 34, TPS7077-TPS7077.	1.6	0
29	A Genomic Predictive Signature for Rigosertib in Lower Risk MDS Derived By Integrating Clinical Response, Mechanism of Action Data and Simulation. Blood, 2016, 128, 5535-5535.	1.4	0
30	Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies. Blood, 2016, 128, 2816-2816.	1.4	0
31	Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4726-34.	7.1	175
32	Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematological Oncology, 2015, 33, 57-66.	1.7	44
33	Targeting the Osteoblast in Myelodysplasia and Acute Myeloid Leukemia. Blood, 2015, 126, 2551-2551.	1.4	1
34	A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia. PLoS ONE, 2014, 9, e108694.	2.5	72
35	Current View of miRNA with Tumor Suppressor Function, Exploring MDS and AML as Models. Signal Transduction Insights, 2014, 3, STI.S12316.	2.0	0
36	A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure. , 2014, 86, 175-182.		40

#	Article	IF	Citations
37	Leukaemogenesis induced by an activating Î²-catenin mutation in osteoblasts. Nature, 2014, 506, 240-244.	27.8	455
38	A Phase II, Multicenter, Open-Label Study of Obatoclax Mesylate in Patients With Previously Untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 534-539.	0.4	35
39	Loss of TET2 Function in Myelodysplastic Syndrome Results in Intragenic Hypermethylation and Alterations in mRNA Splicing. Blood, 2014, 124, 775-775.	1.4	2
40	Molecular Genetic Analysis of Myelodysplastic Syndromes (MDS) Patients with Ring Sideroblasts (RS); Independent Confirmation of Association of SF3B1 Mutations with Better Prognosis. Blood, 2014, 124, 3237-3237.	1.4	2
41	Preliminary International Validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Blood, 2014, 124, 1328-1328.	1.4	0
42	A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies. Blood, 2014, 124, 974-974.	1.4	0
43	A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure. , 2013, , n/a-n/a.		30
44	Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses. Blood, 2013, 122, 2745-2745.	1.4	5
45	Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I. Blood, 2013, 122, 396-396.	1.4	21
46	The biology and treatment of myelodysplastic syndromes. Rinsho Ketsueki/the Japanese Journal of Clinical Hematology, 2013, 54, 1730-6.	0.5	0
47	Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2012, 30, 3376-3382.	1.6	419
48	MDS: Refining existing therapy through improved biologic insights. Blood Reviews, 2012, 26, 73-80.	5.7	16
49	Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS). Journal of Hematology and Oncology, 2012, 5, 18.	17.0	24
50	Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome. Journal of Hematology and Oncology, 2012, 5, 20.	17.0	18
51	The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nature Reviews Cancer, 2012, 12, 849-859.	28.4	129
52	A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediateâ€1 risk myelodysplastic syndrome. Cancer, 2012, 118, 2138-2147.	4.1	40
53	Identification of Dido1 Mutation Associated with Familial Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML). Blood, 2012, 120, 169-169.	1.4	2
54	Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease. Blood, 2012, 120, 677-677.	1.4	16

#	Article	IF	Citations
55	Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I. Blood, 2012, 120, 800-800.	1.4	19
56	Activity of Lenalidomide in a Phase II Single Institution Study in Non-Del(5q) Transfusion Dependent, Results From a Single-Institution Phase II Study. Blood, 2012, 120, 4929-4929.	1.4	3
57	Survival Analysis of Myelodysplastic Syndrome (MDS) Patients with Abnormal Karyotype - A Single Group Experience. Blood, 2012, 120, 4952-4952.	1.4	2
58	Clinical Effect of Point Mutations in Myelodysplastic Syndromes. New England Journal of Medicine, 2011, 364, 2496-2506.	27.0	1,444
59	Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5qâ˜' syndrome. Blood, 2011, 118, 4666-4673.	1.4	97
60	Analysis of Second Primary Malignancies in Lenalidomide-Treated Patients with IPSS Low- or Int-1-Risk Myelodysplastic Syndromes. Blood, 2011, 118, 1704-1704.	1.4	2
61	Final Phase I/II Results of Rigosertib (ON 01910.Na) Hematological Effects in Patients with Myelodysplastic Syndrome and Correlation with Overall Survival,. Blood, 2011, 118, 3822-3822.	1.4	5
62	Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: A case report of sustained hematologic response following an abbreviated exposure. Journal of Hematology and Oncology, 2010, 3, 16.	17.0	12
63	Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS). Blood, 2010, 116, 2910-2910.	1.4	1
64	Thrombocytopenia Predicts for Poor Survival In Patients with Lower Risk Myelodysplastic Syndromes (MDS). Blood, 2010, 116, 4021-4021.	1.4	1
65	Point Mutations In Myelodysplastic Syndromes Are Associated with Clinical Features and Are Independent Predictors of Overall Survival. Blood, 2010, 116, 300-300.	1.4	0
66	Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (TelintraÂ®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. Journal of Hematology and Oncology, 2009, 2, 20.	17.0	48
67	Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood, 2009, 113, 6533-6540.	1.4	62
68	Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature, 2008, 451, 335-339.	27.8	850
69	An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome. PLoS Medicine, 2008, 5, e35.	8.4	145
70	Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1â€"risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood, 2008, 111, 86-93.	1.4	421
71	Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion. New England Journal of Medicine, 2006, 355, 1456-1465.	27.0	1,251
72	Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer, 2006, 106, 1794-1803.	4.1	1,447

#	Article	IF	Citations
73	A Pilot Application of SELDI Serum Proteomics in Bone Marrow Failure Syndromes.. Blood, 2004, 104, 2822-2822.	1.4	0
74	Arsenic Trioxide (TrisenoxÂ®) with/without Thalidomide in Patients with Myelodysplastic Syndromes (MDS) Produces Hematologic Improvement (HI).. Blood, 2004, 104, 4710-4710.	1.4	1
75	Biological Significance of Proliferation, Apoptosis, Cytokines, and Monocyte/Macrophage Cells in Bone Marrow Biopsies of 145 Patients With Myelodysplastic Syndrome. International Journal of Hematology, 2002, 75, 289-297.	1.6	77
76	Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood, 2001, 98, 958-965.	1.4	307
77	The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. British Journal of Haematology, 2001, 115, 881-894.	2.5	98
78	Sequential Activation of Caspase-1 and Caspase-3-like Proteases During Apoptosis in Myelodysplastic Syndromes. Journal of Hematotherapy and Stem Cell Research, 1999, 8, 343-356.	1.8	32
79	Evidence for involvement of tumor necrosis factorâ€Î± in apoptotic death of bone marrow cells in myelodysplastic syndromes. American Journal of Hematology, 1999, 60, 36-47.	4.1	46
80	Correlation of tumor necrosis factor Î± (TNFÎ±) with high Caspase 3-like activity in myelodysplastic syndromes. Cancer Letters, 1999, 140, 201-207.	7.2	64
81	Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leukemia Research, 1996, 20, 891-900.	0.8	189
82	Chromosomes and causation of human cancer and leukemia. LIV. Near-tetraploidy in acute leukemia. Cancer Genetics and Cytogenetics, 1985, 14, 45-59.	1.0	44
83	Developments in the treatment of transfusion-dependent anemia in patients with myelodysplastic syndromes: epidemiology, etiology, genetics, and targeted therapies. Advances in Genomics and Genetics, 0, , 95.	0.8	2